Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Non-Current Deffered Revenue (2016 - 2018)

Neurocrine Biosciences' Non-Current Deffered Revenue history spans 9 years, with the latest figure at $18.1 million for Q4 2018.

  • For Q4 2018, Non-Current Deffered Revenue rose 477.8% year-over-year to $18.1 million; the TTM value through Dec 2018 reached $18.1 million, up 477.8%, while the annual FY2018 figure was $18.1 million, 477.8% up from the prior year.
  • Non-Current Deffered Revenue reached $18.1 million in Q4 2018 per NBIX's latest filing, up from $12.1 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $18.1 million in Q4 2018 to a low of $1.5 million in Q4 2016.
  • Average Non-Current Deffered Revenue over 5 years is $6.8 million, with a median of $10.2 million recorded in 2015.
  • The largest YoY upside for Non-Current Deffered Revenue was 543.46% in 2017 against a maximum downside of 83.45% in 2017.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $1.9 million in 2014, then decreased by 10.7% to $1.7 million in 2015, then decreased by 14.55% to $1.5 million in 2016, then surged by 114.43% to $3.1 million in 2017, then skyrocketed by 477.8% to $18.1 million in 2018.
  • Per Business Quant, the three most recent readings for NBIX's Non-Current Deffered Revenue are $18.1 million (Q4 2018), $12.1 million (Q3 2018), and $10.2 million (Q2 2018).